-
The European Union has approved Zynrelef, a new non-opioid dual-acting painkiller
Time of Update: 2021-03-02
It is worth mentioning that Zynrelef is the first long-acting, slow-release local anaesthetic: in Phase III studies, it has been shown to significantly reduce pain and opioid use within 72 hours compared to the current standard local anaesthetic Bubikain solution for postoperative pain control.
-
Sanofi's Dupixent can reduce severe asthma attacks in children
Time of Update: 2021-03-02
safety results are usually consistent with known safety in patients 12 years of age and older with moderate to severe asthma.
"" Dupixent is the only biologic agent that improves lung function in children in phase III clinical trials, usually consistent with the results in adolescent and adult trials.
-
FDA approves RET inhibitor Gawreto to treat RET fusion positive lung cancer
Time of Update: 2021-03-02
Foundation Pharmaceuticals partner Blueprint Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has approved the precision oncology drug, RET kinase inhibitor Gawreto (pralsetinib), for the treatment of adult patients with metastasis non-small cell lung cancer (NSCLC) that has been confirmed to be RET fusion-positive.
-
GSK shingles vaccine is officially available
Time of Update: 2021-03-02
In clinical trials in 18 countries and regions around the world, Xin'an Lisse showed significant protective effects for shingles, effectively reducing the risk of shingles in people 50 years of age and older.
-
Roche's Glofitamab treatment relapsed/resusive NHL showed strong results
Time of Update: 2021-03-02
Roche recently released the latest data from patients with CD20xCD3 T-cell binding to the dual-specific antibody glofitamab (formerly CD20-TCB) to treat patients with relapsed or incurable (R/R) non-Hodgkin's lymphoma (NHL) at the 25th annual meeting of the European Society of Hematology (EHA).
-
The U.S. will advance Phase III clinical trials of three new crown-candidate vaccines
Time of Update: 2021-03-02
Robert Scully, director of the Department of Infectious Diseases at the University of California, San Diego, told Xinhua that it is relatively easy for candidate vaccines to enter Phase I clinical trials and that conditions such as enabling the immune system to recognize viruses need to be met.
-
Lilly REYVOW treatment of migraine phase 2 clinical results were positive
Time of Update: 2021-03-02
Studies have shown that adult patients with migraine attacks received 100 mg or 200 mg of REYVOW™ C-V (lasmiditan, ramiditan) 3.8 times and 4.6 times more pain relief in two hours of treatment than those who took a placebo.
-
The pioneering Frenchi transferase inhibitor zokinvy will be approved for the market
Time of Update: 2021-03-02
In addition to treating premature aging and premature aging-like nuclear fiber protein disease, Eiger is also developing lolafarnib to treat hepatitis D virus (HDV) infections.
-
The potential COVID-19 drug azithromycin may increase the risk of heart disease
Time of Update: 2021-03-02
"Our findings should lead researchers and clinicians to view azithromycin as a potential treatment for COVID-19 stoppages, and we found that taking these drugs together with drugs that affect electrical impulses in the heart can increase heart events by 40 percent, including fainting, cardiac arrest, and even cardiac arrest," said Haridarshan Patel, a researcher in the Department of Pharmacology, Results and Policy at the UIC School of Pharmacy.
-
Late lymphoma TJC4 has been approved for clinical trials by NMPA
Time of Update: 2021-03-02
The innovation is that lemzoparlimab's ability to minimize binding to normal red blood cells while retaining strong anti-tumor activity reduces the occurrence of clinically severe anemia, a unique advantage that makes it unique in the global CD47 antibody research and development queue.
-
The new target TB testing product was approved for sale in April
Time of Update: 2021-03-02
TB™ simplifies the operation process while producing more accurate results, greatly shortens the testing time, and only a few hours after sampling is completed, which will help improve the diagnostic and screening efficiency of TB, and it is precisely because of the fast, highly stable expression of the target to be tested that this convenient and fast diagnostic product has the expected clinical performance in effectively reducing background interference and immunodeficiency in special populations.
-
Advances have been made in the study of tumor vaccines based on DNA nanoma machines
Time of Update: 2021-03-02
In the early stages, the researchers constructed stimulating responsive DNA self-assembly structure and DNA nanomassers based on physiological pathological marker molecules to achieve precise target delivery and controlled release of functional proteins, nucleic acid drugs, small molecular drugs, etc., and demonstrated good therapeutic results in a variety of tumor models at the animal level (Nature Biotechnol.
-
The FDA approved Qinlock as a four-line treatment for advanced gastrointestinal mesothelioma
Time of Update: 2021-03-02
Recently, the U.S. Food and Drug Administration (FDA) approved the Qinlock tablet as the first new drug to be specifically approved for four-line treatment of advanced gastrointestinal mesothelioma, a tumor that originates in the gastrointestinal tract.
-
The FDA awarded Gilead CD47 a single anti-breakthrough drug
Time of Update: 2021-03-02
. Gilead Sciences recently announced that the U.S. Food and Drug Administration (FDA) has granted magolimab breakthrough drug qualification (BTD), the first anti-CD47 monoclonal antibody to treat newly diagnosed bone marrow growth abnormality syndrome (MDS).
-
Pfizer Xalkori's treatment of APK-positive sALCL has been given priority by the FDA
Time of Update: 2021-03-02
Pfizer announced yesterday that the U.S. Food and Drug Administration (FDA) has accepted and approved the company's application for a new supplement for XALKORI® (sNDA) for the treatment of relapsed patients in children or refragoratic system degenerative large cell lymphoma (ALCL), or mesozoic lymphoma kinase (ALK) positive.
-
Takeda HyQiva has been approved by the European Union to update the label
Time of Update: 2021-03-02
Takeda recently announced that the European Commission (EC) has approved a label update for HyQvia (10%), recombinant human hyalurase, expanding its use to make it the first and only easy-to-use subsurface immunoglobulin replacement therapy for a wider group of secondary immunodeficiency (SID) patients, including adults, adolescents and children.
-
Five-year survival rate of 81.4% for two-year patients treated with NSCLC on the first line of Keytruda in Meshadon
Time of Update: 2021-03-02
The results showed that in patients with metastasis NSCLC with tumor expression PD-L1 (TPS≥50%) and no EGFR or ALC genomic tumor distortion, Keytruda first-line therapy showed long-lasting long-term survival benefits and long-lasting response compared to chemotherapy.
-
Domestic 2nd ADC drug approved for market treatment of two types of lymphoma!
Time of Update: 2021-03-02
Yesterday, Takeda China announced that its targeted innovative drug injection vibtoxidaner (Anshili ®) was officially approved by the State Drug Administration for the treatment of adult CD30-positive recurring or refractory systemic interdational large cell lymphoma (sALCL) and recurring or refractory classic Hodgkin's lymphoma (cHL).
-
Roche's targeted cancer drug Kadcyla Japan has been approved
Time of Update: 2021-03-02
With this latest approval, Kadcyla will provide a new treatment to improve prognosis for HER2-positive early breast cancer patients who receive new assisted (preoperative) treatment without pathological complete remission (pCR).
-
The world's first PD1 knock-on virus-targeted integrated CART treatment for lymphoma has achieved breakthrough results
Time of Update: 2021-03-02
("Bangyao Bio"), a company focused on gene therapy and cell drug research and development, announced a breakthrough in the clinical trial of "PD1 Knockout Virus Point Integration CD19-CART Cell Therapy Recurring Non-Hodgkin's Lymphoma" in collaboration with the First Hospital affiliated with Zhejiang University Medical College.
